Discovery and characterization of a functional scFv for CCR2 inhibition via an extracellular loop

被引:2
|
作者
Jasiewicz, Natalie E. [1 ]
Brown, Adam D. [1 ]
Deci, Michael [2 ]
Matysiak, Silvina [3 ]
Earp, H. Shelton [4 ]
Nguyen, Juliane [1 ]
机构
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengineering & Mol Pharmaceut, Chapel Hill, NC 27599 USA
[2] Univ Buffalo, Dept Pharmaceut Sci, Buffalo, NY USA
[3] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
Chemokine receptors; scFv; Cellular migration; Phenotype switching; In silico; Molecular docking; MONOCYTE CHEMOATTRACTANT PROTEIN-1; SINGLE-CHAIN FV; WEB SERVER; RECEPTOR; BINDING; PF-04634817; MACROPHAGES; ANTAGONIST; EXPRESSION; AFFINITY;
D O I
10.1016/j.ijpharm.2022.122547
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The chemokine receptor CCR2 plays a key role in cellular migration and inflammatory processes. While tremendous progress has been made in elucidating CCR2 function and inhibition, the majority of approaches target its N-terminal domain and less is known about the function of the remaining extracellular loops and their potential as targets. Here, we used phage display to identify an antibody-derived scFv (single chain variable fragment) clone that specifically targets the second extracellular epitope of CCR2 (ECL2) for inhibition. Using in silico molecular docking, we identified six potential primary binding conformations of the novel scFv to the specified CCR2 epitope. In silico molecular dynamic analysis was used to determine conformational stability and identify protein-protein interactions. Umbrella sampling of a range of configurations with incrementally increasing separation of scFv and target generated by force pulling simulations was used to calculate binding energies. Downstream characterization by ELISA showed high binding affinity of the ECL2-scFv to CCR2. Furthermore, we showed that blocking the second extracellular loop inhibits macrophage migration and polarized macrophages towards M1 inflammatory cytokine production as potently as lipopolysaccharide (LPS). These studies highlight the applicability of epitope-specific targeting, emphasize the importance of in silico predictive modeling, and warrant further investigation into the role of the remaining epitopes of CCR2.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Functional characterization of first extracellular loop of chemokine receptor CCR2
    Han, KH
    Green, SR
    Quehenberger, O
    JOURNAL OF LEUKOCYTE BIOLOGY, 1998, : 14 - 14
  • [2] Discovery of a novel CCR2 antagonist as development candidate via divergent SARs of CCR2 and hERG
    Zhang, Xuqing
    Hou, Cuifen
    Hufnagel, Heather
    Markotan, Thomas
    Lanter, James
    Cai, Chaozhong
    Singer, Monica
    Opas, Evan
    McKenney, Sandra
    Crysler, Carl
    Johnson, Dana
    Sui, Zhihua
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [3] Characterization of the CCR2 chemokine receptor: Functional CCR2 receptor expression in B cells
    Frade, JMR
    Mellado, M
    del Real, G
    Gutierrez-Ramos, JC
    Lind, P
    Martinez, C
    JOURNAL OF IMMUNOLOGY, 1997, 159 (11): : 5576 - 5584
  • [4] Role of the first extracellular loop in the functional activation of CCR2 - The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling
    Han, KH
    Green, SR
    Tangirala, RK
    Tanaka, S
    Quehenberger, O
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) : 32055 - 32062
  • [5] Role of the first extracellular loop in the functional activation of CCR2: The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling
    Han, Ki Hoon
    Green, Simone R.
    Tangirala, Rajendra K.
    Tanaka, Seiya
    Quehenberger, Oswald
    Journal of Biological Chemistry, 274 (45): : 32055 - 32062
  • [6] Discovery of novel monoaryl CCR2 antagonists
    Lanter, James C.
    Markotan, Thomas P.
    Subasinghe, Nalin L.
    Lawson, Edward C.
    Hou, Cuifen
    Opas, Evan
    McKenney, Sandra
    Crysler, Carl
    O'Neill, John
    Johnson, Dana
    Sui, Zhihua
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [7] The discovery of novel cyclohexylamide CCR2 antagonists
    Lanter, James C.
    Markotan, Thomas P.
    Zhang, Xuqing
    Subasinghe, Nalin
    Kang, Fu-An
    Hou, Cuifen
    Singer, Monica
    Opas, Evan
    McKenney, Sandra
    Crysler, Carl
    Johnson, Dana
    Molloy, Christopher J.
    Sui, Zhihua
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (24) : 7496 - 7501
  • [8] Functional expression of CCR2 by human eosinophils
    Dunzendorfer, S
    Woell, E
    Frade, JMR
    Mellado, M
    Martinez-A, C
    Wiedermann, CJ
    JOURNAL OF LEUKOCYTE BIOLOGY, 2000, : 16 - 16
  • [9] Inhibition of corneal neovascularization by genetic ablation of CCR2
    Ambati, BK
    Joussen, AM
    Kuziel, WA
    Adamis, AP
    Ambati, J
    CORNEA, 2003, 22 (05) : 465 - 467
  • [10] CCR2 inhibition: a panacea for diabetic kidney disease?
    Weir, Matthew R.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (09): : 666 - 667